How Build Back Better Would Affect Drug Costs
Provisions in the bill that would lower prescription drug costs and reduce federal drug spending would take effect over the next several years, starting in 2023.
View the Latest: Build Back Better
Filter
-
-
Medicaid Enrollment Churn and Implications for Continuous Coverage Policies
Issue BriefRecent policy actions and proposals in Medicaid have renewed focus on the problem of churn, or temporary loss of coverage in which enrollees disenroll and then re-enroll within a short period of time. We find that 10% of full-benefit enrollees have a gap in coverage of less than a year, and rates are higher for children and adults compared to aged and people with disabilities. Churn has implications for access to care as well as administrative costs faced by states.
-
Build Back Better Would Change the Ways Low-Income People get Health Insurance
Issue BriefThe Build Back Better Act would make a number of changes to the way people get health insurance and how health care is financed, including by temporarily closing the Medicaid coverage gap.
-
Medicaid: What to Watch in 2022
Issue BriefAs 2022 kicks off, a number of issues are at play that could affect coverage and financing under Medicaid. This issue brief examines key issues to watch in Medicaid in the year ahead.
-
Millions of Medicare Beneficiaries Use Prescription Drugs That Could Be Subject to Price Negotiation, But Build Back Better Act Provision Exempts Many Drugs With High Federal Spending
News ReleaseTwenty drugs and dozens of insulin products used by 8.5 million Medicare beneficiaries would be subject to government drug price negotiation if the Build Back Better Act (BBBA) were enacted and fully implemented in 2022, according to a new KFF analysis.
-
Explaining the Prescription Drug Provisions in the Build Back Better Act
Issue BriefThe Build Back Better Act includes several provisions that would lower prescription drug costs for people with Medicare and private insurance and reduce drug spending by the federal government and private payers. This brief summarizes these provisions and discusses the expected effects on people, program spending, and drug prices and innovation.
-
Public Health Infrastructure and Pandemic Preparedness Provisions in the Build Back Better Act
Issue BriefThis brief summarizes funding for public health infrastructure as well as pandemic preparedness as specified in the Build Back Better Act introduced in the House.
-
Dec. 8 Event: Unpacking the Prescription Drug Provisions of the Build Back Better Act
Event Date:EventAs the Build Back Better Act shifts from the House to the Senate, there’s considerable interest in provisions that would lower the cost of prescription drugs.
-
Simulating the Impact of the Drug Price Negotiation Proposal in the Build Back Better Act
Issue BriefThe Build Back Better Act (BBBA) includes a range of health and other proposals supported by President Biden, including a proposal to allow the federal government to negotiate the price of some prescription drugs covered under Medicare Part B (administered by physicians) and Medicare Part D (retail outpatient drugs). This brief illustrates the potential scope of the drug price negotiation proposal in the BBBA. This analysis is designed to highlight the types of Medicare-covered drugs that could be subject to negotiation, and which of the current top-spending drugs covered by Part B and Part D could be subject to price negotiation, and in what years, if the BBBA is enacted.
-
Medicaid Financing and the U.S. Territories: Implications of The Build Back Better Act
Policy WatchThe U.S territories have faced an array of longstanding fiscal and health challenges that were exacerbated by recent natural disasters and the COVID-19 pandemic. This policy watch examines how Medicaid funding for the territories works, the current allotments, and how the Build Back Better Act (BBA) would change Medicaid funding for the territories going forward. While a version of BBBA has passed the house, its fate in the Senate remains uncertain.